Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Surfactant >  Caionic surfactants >  DLin-KC2-DMA

DLin-KC2-DMA

Basic information Safety Supplier Related

DLin-KC2-DMA Basic information

Product Name:
DLin-KC2-DMA
Synonyms:
  • DLin-KC2-DMA
  • 1,3-Dioxolane-4-ethanamine, N,N-dimethyl-2,2-di-(9Z,12Z)-9,12-octadecadien-1-yl-
  • 2-(2,2-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethanamine
  • 2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine
  • DLin-KC-2-DMA,inhibit,Inhibitor,DLin KC2 DMA,DLinKC2DMA
  • KC2
CAS:
1190197-97-7
MF:
C43H79NO2
MW:
642.09
Mol File:
1190197-97-7.mol
More
Less

DLin-KC2-DMA Chemical Properties

Boiling point:
668.1±40.0 °C(Predicted)
Density 
0.885±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C,unstable in solution, ready to use.
solubility 
Soluble in Ethanol, DMSO, DMF
pka
9.32±0.28(Predicted)
form 
Liquid
color 
Colorless to light yellow
InChIKey
LRFJOIPOPUJUMI-MNMREVDWSA-N
SMILES
O1CC(CCN(C)C)OC1(CCCCCCCCC=CCC=CCCCCC)CCCCCCCC/C=C\C/C=C\CCCCC
More
Less

DLin-KC2-DMA Usage And Synthesis

Description

DLin-KC2-DMA is a useful ionizable lipid for siRNA delivery. It was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates.

Uses

DLin-KC2-DMA, also known as KC2 (2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane) is an optimized ionizable cationic lipid (ICL) with a reported apparent pKa of 6.7. This pKa ensures an efficient encapsulation of nucleic acid polymers at low pH, a nearly neutral surface charge for the LNPs in the circulation at physiological pH, and a high positive surface charge at endosomal pH. More recently, it was determined that LNPs containing KC2 generated liposomal structures when the KC2 is protonated at pH 4, while forming electron-dense structures at pH 7.4. It is an ionizable cationic lipid that has been used to form lipid nanoparticles (LNPs) encapsulating siRNA or plasmid DNA for use in vitro and in vivo. LNPs containing DLin-KC2-DMA selectively accumulate in mice's liver after intravenous or intramuscular administration or localize to the retinal pigment epithelium and Müller glia after subretinal administration. DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting F7 mRNA, which encodes Factor VII, reduce serum Factor VII levels in mice. Intravenous administration of DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting AR mRNA, which encodes the androgen receptor, decreases serum prostate-specific antigen (PSA) and tumour androgen receptor levels in an LNCaP prostate cancer mouse xenograft model[1].

References

[1] Ramezanpour, M. et al. “Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function?.” Nanoscale 30 (2019): 14141–14146.

DLin-KC2-DMASupplier

Shanghai Chaolan Chemical Technology Center Gold
Tel
021-QQ:65489617 15618227136
Email
Sales@ATKchemical.com
Wuhan Topule Gold
Tel
+86-02787215551 +86-19945035818
Email
2936752263@qq.com
Shanghai Changyu Medical Technology Co. Ltd. Gold
Tel
+86-13301875428
Email
sales@changyuhe.com
Wuxi Donghe Pharmaceutical Technology Co., Ltd. Gold
Tel
63313187 15358055255
Email
63313187@qq.com
Chengdu Junepharma Technology Co., Ltd Gold
Tel
19938173342 19181793067
Email
1486288711@qq.com